Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Fresenius Medical Care AG & Co. KGaA (FMS) has a Wall Street consensus price target of $28.00, based on estimates from 18 covering analysts. With the stock currently trading at $23.46, this represents a potential upside of +19.4%. The company has a market capitalization of $13.60B.
Analyst price targets range from a low of $28.00 to a high of $28.00, representing a 0% spread in expectations. The median target of $28.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 5 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, FMS trades at a trailing P/E of 11.8x and forward P/E of 9.9x. The forward PEG ratio of 1.94 indicates reasonable valuation for growth. Analysts expect EPS to grow +38.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.39, with bear and bull scenarios of $11.15 and $38.25 respectively. Model confidence stands at 54/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FMS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFresenius Medical Care AG & Co. KGaA (FMS) has a consensus 12-month price target of $28, implying 19.4% upside from $23.46. The 18 analysts covering FMS see moderate appreciation potential.
FMS has a consensus rating of "Hold" based on 18 Wall Street analysts. The rating breakdown is mixed, with 12 Hold ratings making up the largest segment. The consensus 12-month price target of $28 implies 19.4% upside from current levels.
With a forward P/E of 9.8937x, FMS trades at a relatively low valuation. The consensus target of $28 implies 19.4% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $28 for FMS, while the most conservative target is $28. The consensus of $28 represents the median expectation. Our quantitative valuation model projects a bull case target of $38 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
FMS is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FMS stock forecast based on 18 Wall Street analysts shows a consensus price target of $28, with estimates ranging from $28 (bear case) to $28 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $11/$38.
Our quantitative valuation model calculates FMS's fair value at $20 (base case), with a bear case of $11 and bull case of $38. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 54/100.
FMS trades at a forward P/E ratio of 9.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 11.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on FMS, with a "Hold" consensus rating and $28 price target (19.4% upside). 5 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FMS analyst price targets range from $28 to $28, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28 consensus represents the middle ground. Our model's $11-$38 range provides an independent fundamental perspective.